Evidence map›Paper›PMID 34282761›Full record

ArticleCancers2021

Fibroblast Activation Protein Expressing Mesenchymal Cells Promote Glioblastoma Angiogenesis.

Eva Balaziova, Petr Vymola, Petr Hrabal, Rosana Mateu, Michal Zubal, Robert Tomas, David Netuka, Filip Kramar, Zuzana Zemanova, Karla Svobodova and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. FAPExperimental & molecular medicine · 2026
    Article
  3. Article
  4. Comparison of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. NovelPharmaceuticals (Basel, Switzerland) · 2023
    Article
  17. Synthesis and Preclinical Evaluation of Three NovelMolecules (Basel, Switzerland) · 2023
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Eva BalaziovaLaboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic.
Petr VymolaLaboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic.
Petr HrabalDepartment of Pathology, Military University Hospital, 169 02 Prague, Czech Republic.
Rosana MateuLaboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic.ORCID 0000-0001-6532-9219
Michal ZubalLaboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic.
Robert TomasDepartments of Neurosurgery, Na Homolce Hospital, 150 00 Prague, Czech Republic.ORCID 0000-0001-6619-9938
David NetukaDepartment of Neurosurgery and Neurooncology, First Faculty of Medicine, Charles University and Military University Hospital, 168 02 Prague, Czech Republic.ORCID 0000-0001-8609-4789
Filip KramarDepartment of Neurosurgery and Neurooncology, First Faculty of Medicine, Charles University and Military University Hospital, 168 02 Prague, Czech Republic.ORCID 0000-0003-0833-2360
Zuzana ZemanovaCenter of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic.ORCID 0000-0001-6007-4640
Karla SvobodovaCenter of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic.
Marek BrabecInstitute of Computer Science, The Czech Academy of Sciences, 128 00 Prague, Czech Republic.
Aleksi SedoLaboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic.ORCID 0000-0002-3247-5436
Petr BusekLaboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic.ORCID 0000-0003-2158-4837
Charles University · CZCzech Academy of Sciences · CZMilitary University Hospital Prague · CZNa Homolce Hospital · CZ

Funding

Grantová Agentura, Univerzita Karlova 1084120Ministerstvo Školství, Mládeže a Tělovýchovy CZ.02.1.01/0.0/0.0/16_019/0000785Ministerstvo Školství, Mládeže a Tělovýchovy LM2018133Ministerstvo Zdravotnictví Ceské Republiky Conceptual development of research organization 64165, General University Hospital in Prague, Czech RepublicMinisterstvo Zdravotnictví Ceské Republiky NU21-04-00100Univerzita Karlova v Praze Progres Q28/1LFUK
6 · The paper itself

Abstract

Fibroblast activation protein (FAP) is a membrane-bound protease that is upregulated in a wide range of tumours and viewed as a marker of tumour-promoting stroma. Previously, we demonstrated increased FAP expression in glioblastomas and described its localisation in cancer and stromal cells. In this study, we show that FAP

Indexed as

angiogenesisangiopoietinfibroblast activation proteinglioblastomamicroenvironmentseprasevessel destabilisation

Identifiers

PMID34282761
PMCPMC8267680
OpenAlexW3176048753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.